Promis Neurosciences Inc. · NASDAQ:PMN
Promis Neurosciences — Investor Presentation (January 2025)
34 slides from Promis Neurosciences's investor presentation, Jan 27, 2025
Slide 1: Targeting the underlying cause of neurodegenerative diseases
NASDAQ: PMN Targeting the underlying cause of neurodegenerative diseases
Slide 2: Legal Disclaimers
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Legal Disclaimers This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materia
Slide 3: Unique potential in areas of great unmet need
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Unique potential in areas of great unmet need Clinical-stage biopharma with pipeline selectively targeting specific, disease-causing misfolded proteins 3 • Unique selectivity may create potential to address the unmet need for safer, more
Slide 4: PRECISE-AD: Lead program PMN310 in ongoing Phase 1b study in Alzheimer's patients
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PRECISE-AD: Lead program PMN310 in ongoing placebo-controlled Phase 1b clinical study in Alzheimer’s patients 4 Humanized monoclonal antibody designed to bind toxic amyloid-beta oligomers (AbOs), NOT monomers or plaques Phase 1a: PMN310 w
Slide 5: Experienced Leadership Team
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Experienced Leadership Team 5 Josh Mandel-Brehm, M.B.A. Independent Director Maggie Shafmaster, Ph.D., J.D. Lead Independent Director Neil K. Warma, M.B.A., B.Sc. Chief Executive Officer William Wyman, M.B.A. Independent Director Patrick
Slide 6: Lead programs targeting growing opportunities in neurodegeneration
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Lead programs targeting growing opportunities in neurodegeneration 6 Clinical Phase 1b Alzheimer’s Disease (AD) Amyotrophic Lateral Sclerosis (ALS) Synucleinopathies (MSA, PD, DLB, etc.)* *MSA - Multiple system atrophy; PD - Parkinson’s d
Slide 7: The ProMIS Solution – precision medicine and AI driving selective monoclonal antibodies
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential The ProMIS Solution – The best of precision medicine and AI driving development of selective monoclonal antibodies Our Novel, Proprietary Target Discovery Engine + Antibody Development Computational Modeling Epitope Construct & Antibody C
Slide 8: Platform generating robust pipeline targeting toxic misfolded proteins
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Product Candidate Target Protein Disease Indication(s) Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 ANTIBODY PMN310 Amyloid-Beta AD PMN267 TDP-43 ALS PMN442 Alpha-Synuclein MSA1 VACCINE PMN440 Alpha-Synuclein Vaccine Multiple synucleino
Slide 9: Lead Clinical Candidate PMN310 in Alzheimer's Disease
Lead Clinical Candidate PMN310 in Alzheimer’s Disease Selectivity for Toxic Aβ Oligomers
Slide 10: Amyloid-beta protein exists in different forms and concentrations
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Amyloid-beta protein exists in different forms and different concentrations 10 Aβ Monomers: Abundant, produced over lifetime Have a beneficial biologic role Highly toxic Aβ Oligomers: Small, soluble clusters of Aβ – Main driver of disease
Slide 11: Soluble toxic Aβ oligomers, not plaque, are the most neuropathogenic species
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Soluble toxic Aβ oligomers, not plaque, are the most neuropathogenic Aβ species in Alzheimer’s Disease • Synapse abnormalities and memory impairment correlate poorly with plaque burden in human and mouse AD1,2 • Aβ monomers and plaque hav
Slide 12: Selectivity for toxic AβOs creates potential for improved efficacy & safety
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Selectivity for toxic AβOs creates potential for improved efficacy & safety Why Target Toxic AβOs? • AbOs destroy synapses leading to neurodegeneration; believed to be THE key driver of AD progression over insoluble plaques • Antibodies t
Slide 13: Specific targeting of toxic Aβ oligomers needed for efficacy and safety
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Specific targeting of toxic Aβ oligomers is needed for increased efficacy and improved safety profile Avoiding off-target delivery of drug, to more plentiful monomers and plaque • Most drugs cross-react with several species of Ab • Less d
Slide 14: Importance of selectivity for toxic amyloid-β oligomers
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Importance of selectivity for toxic amyloid-β oligomers (AβOs) 14 Monomers Oligomers Plaque Abundant, produced over lifetime Have a beneficial biologic role Small, soluble clusters of Aβ – Main driver of disease Damage the brain cells and
Slide 15: PMN310 – Demonstrated best-in-class resistance to Aβ monomer competition
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN310 – Demonstrated best-in-class resistance to Aβ monomer competition • Antibodies that failed in the clinic had toxic oligomer binding abrogated by monomer exposure • Antibodies with positive clinical trial data were more resistant to
Slide 16: Plaque-binding antibodies associated with increased ARIA-E risk; PMN310 shows no plaque binding
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Plaque-binding antibodies associated with increased risk of ARIA-E PMN310 shows no detectable plaque binding PMN310 – Only antibody exclusively targeting toxic oligomers while avoiding Aβ plaque in preclinical studies 16 Reported ARIA rat
Slide 17: PMN310 high-dose treatment in AD mice did not cause microhemorrhages
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential NO ARIA-H No microhemorrhages observed in brain sections from 29 vehicle control (placebo) mice and 29 PMN310-treated mice PMN310 – High-dose treatment in AD mice did not cause microhemorrhages (ARIA-H) 17 • Plaque-binding antibodies have
Slide 18: PMN310 preserved memory in AD mouse model
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN310 preserved memory in AD mouse model 18 #p<0.05 vs AbO; *p<0.05 vs vehicle Gibbs et al, 2019, Scientific Reports AbO +/- PMN310 7 days Injection of toxic AbO in the brain ventricles of mice destroys their ability to remember and dist
Slide 19: PMN310 preserved memory and learning in AD mouse model
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN310 preserved memory and learning in AD mouse model 19 *p<0.05 vs vehicle-treated hAPP-Tg for both vehicle-treated non-Tg and PMN310-treated Tg mice Kaplan et al, 2024, bioRxiv, https://www.biorxiv.org/content/10.1101/2024.04.20.590412
Slide 20: PMN310 Phase 1a single ascending dose study results
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Healthy volunteers (N=8 per cohort) First subject dosed Nov. 2023 Dose 2.5 mg/kg (N = 6:2) Dose 5 mg/kg (N = 6:2) Dose 10 mg/kg (N = 6:2) Dose 20 mg/kg (N = 6:2) Dose 40 mg/kg (N = 6:2) PMN310 Placebo-Controlled Study (2.5-40 mg/kg) Posit
Slide 21: PRECISE-AD: PMN310 Phase 1b MAD trial design in AD patients
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Clinical endpoints (cognition) measured at baseline and months 6 & 12: • CDR-SB (Clinical Dementia Rating, Sum of Boxes) • ADAS-cog • ADAS-ADL • IADRS • Clinical Global Impression of Change CSF/ Plasma Biomarkers: 0, 3, 6, 9, 12 month • p
Slide 22: PRECISE-AD: 6-month interim analysis and final analysis
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PRECISE-AD: 6-month interim analysis to show impact of biomarker and incidence of ARIA; Final analysis to include clinical outcome measures Biomarker Relevance p-tau 217 Measure of disease progression p-tau 243 Measure of downstream tau p
Slide 23: PMN310 target product profile
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN310 target product profile 23 CATEGORY DETAILS Indication Treatment of Alzheimer's Disease (AD) Mechanism of Action Humanized monoclonal antibody selectively targeting toxic amyloid-beta (Aβ) oligomers Formulation Intravenous (IV) admi
Slide 24: Lead Pipeline Candidates
Lead Pipeline Candidates Antibody and Vaccine Candidates Targeting a Range of Neurodegenerative Diseases
Slide 25: PMN267: Lead antibody candidate targeting pathogenic TDP-43
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN267: Lead antibody candidate targeting pathogenic TDP-43 25 Why TDP-43? • TAR DNA-binding protein 43 (TDP-43) essential to neuronal cell survival1; plays important roles in RNA regulation • Pathogenic TDP-43 aggregates frequently obser
Slide 26: PMN267 advancing to IND-enabling studies
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN267 advancing to IND-enabling studies 26 Nuclei Misfolded DNLS-TDP-43 (HA Tag) ProMIS mAb Merge Potential across neurodegenerative disease with TDP-43 proteinopathy including ALS, Frontotemporal dementia (FTD), AD, and Limbic-predomina
Slide 27: PMN442: Lead antibody candidate targeting toxic α-Synuclein
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN442: Lead antibody candidate targeting toxic α-Synuclein 27 Why Alpha-Synuclein (α-syn)? • α-syn plays a role in synaptic activity, including regulating release of dopamine and maintaining synaptic vesicles • In synucleinopathies, α-sy
Slide 28: PMN442 advancing to IND-enabling studies
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN442 advancing to IND-enabling studies 28 CONTROL a-SYN OLIGOMERS a-SYN OLIGOMERS + PMN442 PMN442 has been humanized in a human IgG1 framework for IND-enabling studies Potential across range of synucleinopathies including Multiple Syste
Slide 29: The ProMIS platform potential in vaccine applications
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential The ProMIS platform potential in vaccine applications Epitopes of toxic misfolded proteins identified by the ProMIS platform can also potentially be used for direct vaccination to induce production of selective protective antibodies • Pur
Slide 30: PMN311: Positive early results presented at AAIC 2024
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential PMN311: Positive early results presented at AAIC 2024 30 • Testing of 15 possible combinations of 1 to 4 conformational Aβ oligomer epitopes in mouse vaccination studies led to the selection of PMN311 as the lead vaccine candidate for fur
Slide 31: Platform generating robust pipeline of selective candidates
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Product Candidate Target Protein Disease Indication(s) Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 ANTIBODY PMN310 Amyloid-Beta AD PMN267 TDP-43 ALS PMN442 Alpha-Synuclein MSA1 VACCINE PMN440 Alpha-Synuclein Vaccine Multiple synucleino
Slide 32: Key Anticipated Milestones
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Enrollment of Cohorts 1 (5 mg/kg), 2 (10 mg/kg), 3 (20 mg/kg) Initiated PRECISE-AD Key Anticipated Milestones 32 H1’25 H2’25 H1’26 H2’26 Achieving these milestones will drive the company’s strategic growth and potential for transformative
Slide 33: Committed to patients with novel approach to battling neurodegenerative diseases
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Committed to patients with novel approach to battling neurodegenerative diseases 33 Clinical data and milestones could unlock significant potential and demonstrate proof of concept for PMN310 in AD Advancing preclinical pipeline could fur
Slide 34: For further information, contact
NASDAQ: PMN For further information, contact: info@promisneurosciences.com
ProMIS Neurosciences — Investor Presentation (January 2025) on 6ix